Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 337-343

  Schiavo, Ada Lo ^a   Puca, Rosa Valentina ^a   Ruocco, Vincenzo ^a   Ruocco, Eleonora ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CLOBETASOL PROPIONATE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEFLAZACORT; DICLOXACILLIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MESNA; METHOTREXATE; MINOCYCLINE; MITOMYCIN C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; SULFAMETHOXYPYRIDAZINE; SULFAPYRIDINE; TACROLIMUS; TETRACYCLINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ALLERGIC REACTION; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; APHTHOUS STOMATITIS; ARTICLE; ASEPTIC MENINGITIS; ASTHENIA; AUTOIMMUNE SKIN DISEASE; BACKACHE; BRITTLE FINGERNAIL; BRONCHOSPASM; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CHILL; CLINICAL TRIAL; CONFUSION; CONGENITAL MALFORMATION; CONJUNCTIVITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECZEMA; EDEMA; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA; ESOPHAGITIS; FEVER; FLUSHING; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GINGIVA HYPERPLASIA; HAIR DISCOLORATION; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HEPATITIS B; HICCUP; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; LETHARGY; LEUKOPENIA; LINEAR IMMUNOGLOBULIN A DERMATOSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MACULOPAPULAR RASH; MUCOCUTANEOUS REACTION; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; MUTAGENICITY; MYALGIA; NAIL COLOR DEFECT; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PANCREATITIS; PANCYTOPENIA; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS; PEPTIC ULCER; PHLEBITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RASH; RHINITIS; RIGOR; SIDE EFFECT; SKIN CANCER; SKIN DISCOLORATION; SPONTANEOUS ABORTION; STOMACH PAIN; THROAT IRRITATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; TINNITUS; TREMOR; TUMOR LYSIS SYNDROME; URTICARIA; VIRUS INFECTION; VOMITING; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASES; EVALUATION STUDY; PRACTICE GUIDELINE; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; AZATHIOPRINE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PEMPHIGUS; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 77953568957     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.06.018     Document Type: Article

References (53)

1. Schmidt E., Zillikens D. Autoimmune and inherited subepidermal blistering diseases: advances in the clinic and the laboratory. Adv Dermatol 2000, 16:113-157.
2. Ruocco V., Ruocco E. Pemphigus and environmental factors. G Ital Dermatol Venereol 2003, 138:299-309.
3. Ahmed A.R., Dahl M.V. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003, 139:1051-1059.
4. Bystryn J.C., Steinman N.M. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996, 132:203-212.
5. Kazlow Stern D., Tripp J.M., Ho V.C., Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005, 23:259-300.
6. Dutz J.P., Ho V.C. Immunosuppressive agents in dermatology. An update. Dermatol Clin 1998, 16:235-251.
7. Nousari H.C., Sragovich A., Kimyai-Asadi A., Orlinsky D., Anhalt G.J. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999, 40:265-268.
8. Shah N., Green A.R., Elgart G.W., Kerdel F. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000, 42:85-88.
9. Chave T.A., Mortimer N.J., Shah D.S., Hutchinson P.E. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004, 151:1107-1108.
10. Schmidt E., Bröcker E.B., Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008, 34:56-64.
11. Harman K.E., Albert S., Black M.M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
12. Mimouni D., Nousari C.H., Cummins D.L., Kouba D.J., David M., Anhalt G.J. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003, 49:1059-1062.
13. Ruocco E., Baroni A., Wolf R., Ruocco V. Life-threatening bullous dermatoses: Pemphigus vulgaris. Clin Dermatol 2005, 23:223-226.
14. Huilgol S.C., Black M.M. Management of the immunobullous disorders. II. Pemphigus. Clin Exp Dermatol 1995, 20:283-293.
15. Hymes S.R., Jordon R.E. Pemphigus foliaceus. Use of antimalarial agents as adjuvant therapy. Arch Dermatol 1992, 128:1462-1464.
16. Hertzberg M.S., Schifter M., Sullivan J., Stapleton K. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin's lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000, 63:105-106.
17. Nanda M., Nanda A., Al-Sabah H., Dvorak R., Alsaleh Q.A. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol 2007, 46:767-769.
18. Meijs M., Mekkes J., van Noesel C., et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma without Castleman's disease; treatment with rituximab. Int J Dermatol 2008, 47:632-634.
19. Barnadas M., Roe E., Brunet S., et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 2006, 20:69-74.
20. Barbetakis N., Samanidis G., Paliouras D., et al. Paraneoplastic pemphigus regression after thymoma resection. World J Surg Oncol 2008, 6:83.
21. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
22. Lebeau S., Clivaz L., Fontao L., Borradori L. Bullous pemphigoid, an autoimmune blistering disease with protean clinical manifestations. Review of recent advances from the bench to the bedside. G Ital Dermatol Venereol 2006, 141:495-505.
23. Saw V.P., Dart J.K. Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf 2008, 6:128-142.
24. Canizares M.J., Smith D.I., Conners M.S., Maverick K.J., Heffernan M.P. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006, 142:1457-1461.
25. Chorzelski T.P., Jablonska S., Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol 1991, 9:383-392.
26. Pulimood S., Ajithkumar K., Jacob M., George S., Chandi S.M. Linear IgA bullous dermatosis of childhood: treatment with dapsone and co-trimoxazole. Clin Exp Dermatol 1997, 22:90-91.
27. Talhari C., Mahnke N., Ruzicka T., Megahed M. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent. Clin Exp Dermatol 2005, 30:297-298.
28. Lewis M.A., Yaqoob N.A., Emanuel C., Potts A.J. Successful treatment of oral linear IgA disease using mycophenolate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 103:483-486.
29. Farley-Li J., Mancini A.J. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol 2003, 139:1121-1124.
30. Goebeler M., Seitz C., Rose C., et al. Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins. Br J Dermatol 2003, 149:912-914.
31. Wallet-Faber N., Franck N., Batteux F., et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology 2007, 215:252-255.
32. Sadler E., Schafleitner B., Lanschuetzer C., et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br J Dermatol 2007, 157:417-419.
33. Crichlow S.M., Mortimer N.J., Harman K.E. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007, 156:194-196.
34. Gaudy-Marqueste C. Autre immunosuppresseurs: azathioprine (Imurel®), mycophénolate mofétil (Cellcept®), cyclophosphamide (Endoxan®). Ann Dermatol Venereol 2007, 134:949-956.
35. Momeni A.Z., Iraji F., Aminjavaheri M., Emami M.R., Momeni A. The use of oral cyclophosphamide with dexamethasone pulse therapy in the treatment of pemphigus vulgaris. J Dermatolog Treat 2007, 18:275-278.
36. Ogawa Y., Adachi A., Okamoto M., Hashimoto T., Tomita Y. A case of refractory bullous pemphigoid with plasmapheresis-associated thrombopenia: efficacy of pulsed intravenous cyclophosphamide therapy. J Dermatol 2004, 31:651-654.
37. Pandya A.G., Warren K.J., Bergstresser P.R. Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide. Arch Dermatol 1997, 133:245-247.
38. Yesudian P.D., Armstrong S., Cawood J.I., Allan R.B., Mendelsohn S.S., Kaye S.B. Mucous membrane pemphigoid: management of advanced ocular disease with intravenous cyclophosphamide and amniotic membrane transplantation. Br J Dermatol 2005, 153:692-694.
39. Patel A.A., Swerlick R.A., McCall C.O. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006, 55:369-389.
40. Tan B.B., Lear J.T., Gawkrodger D.J., English J.S. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol 1997, 136:351-355.
41. Doutre M.S. Ciclosporine: Néoral®, Sandimmun®. Ann Dermatol Venereol 2007, 134:929-933.
42. Benoit S., Bröcker E.B., Schmidt E. Current treatment of pemphigus. G Ital Dermatol Venereol 2007, 142:363-380.
43. Azaña J.M., de Misa R.F., Boixeda J.P., Ledo A. Topical cyclosporine for cicatricial pemphigoid. J Am Acad Dermatol 1993, 28:134-135.
44. Holland E.J., Olsen T.W., Ketcham J.M., et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993, 12:413-419.
45. Lehman J.S., Mueller K.K., Schraith D.F. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy?. Arch Dermatol 2008, 144:783-785.
46. Lapeyre H., Joly P. Rituximab: Mabthera®. Ann Dermatol Venereol 2007, 134:968-971.
47. Schmidt E., Seitz C.S., Benoit S., Bröcker E.B., Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156:352-356.
48. Schmidt E., Hunzelmann N., Zillikens D., Bröcker E.B., Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006, 31:503-508.
49. Mimouni D., Anhalt G.J., Cummins D.L., Kouba D.J., Thorne J.E., Nousari C.H. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003, 139:739-742.
50. Marzano A.V., Dassoni F., Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006, 17:370-376.
51. Olszewska M., Kolacinska-Strasz Z., Sulej J., et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007, 8:85-92.
52. Chams-Davatchi C., Esmaili N., Daneshpazhooh M., et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007, 57:622-628.
53. Beissert S., Werfel T., Frieling U., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006, 142:1447-1454.